CHF 6297

Drug Profile

CHF 6297

Alternative Names: CHF-6297; CHI-91040; MAPK14 inhibitor

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pulmagen Therapeutics
  • Developer Chiesi Farmaceutici
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Jul 2017 Chiesi Farmaceutici suspends patient enrolment for precaution due to safety issues in preclinical studies in the phase I/II CHF6297 FIH trial in Chronic obstructive pulmonary disease in United Kingdom (Inhalation) (NCT02815488)
  • 19 May 2017 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Lung disorders presented at the 113th International Conference of the American Thoracic Society (ATS-2017)
  • 03 Sep 2016 Pharmacodynamics and pharmacokinetics data from a in-vitro studies presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top